RMS has established this critical information and insights page to provide the latest COVID-19 developments. As the situation continues to evolve, our goal is to help you strengthen your understanding and manage the impacts from COVID-19. See below for our latest risk assessment reports, COVID-19 blogs, webinar series, RMS media coverage, and additional resources to get you up to speed on the risk surrounding COVID-19 and how to respond.
Explore COVID-19 Expertise from RMS
Dexamethasone: The First Life-Saving Drug for Very Sick CO...
In the history of medicine, there have been many major discoveries that were made serendipitously. Drugs which have been developed to treat one illness have proven effective for quite another. This apparently haphazard nature of medical discovery gives rise to what can appear to be a random walk of medical progress, a phenomenon which is captured in the RMS LifeRisks longevity model. Dexamethasone belongs to a class of medicines known as corticosteroids, or more simply, steroids. It is used to treat a va...
A Model Approach
COVID-19 is shining a spotlight on the need for predictive infectious disease modeling to help insurers project the onset and spread of costly outbreaks.
Twenty-First Century Pandemic Risk Management
The tactics of warfare are learned on the latest field of battle. The same is true for the management of pandemics, where defensive measures require the full engagement of the state. Outside of Africa, the last deadly epidemic in 2003 was caused by another coronavirus: SARS (severe acute respiratory syndrome). SARS brought a “partial pandemic,” as the outbreak was largely restricted to some cities in China and a few neighboring countries. However, for the cities in the front line this was the real thing, requ...
Coronavirus Blog Series
Review the latest COVID-19 blogs from pandemic risk and medical experts at RMS
Infectious Disease Modeling
Examine the science behind pandemic risk assessment
COVID-19 Assessment Report
RMS looks at the spread and overall mortality using the RMS Infectious Disease Model
RMS and Willis Re discuss the insurance implications of COVID-19
Coronavirus Will Cost Businesses Billions
Two years ago Munich Re, the reinsurance giant, tried to start underwriting a new kind of insurance — one that would make a company whole if its business tanked in an epidemic. For months, there were no takers.
Access Information About RMS LifeRisks
Bring an integrated view of mortality shock and longevity trend risks underpinned by detailed medical research into your life, annuity, and pensions portfolios.
LifeRisks is a cloud-based software platform that delivers the models and data to perform portfolio specific analytics for the management of mortality and longevity risk.
Ready to Work Smarter?